T1	p 111 182	in patients with acute myeloid leukemia and myelodysplastic syndromes :
T2	p 185 193	Japanese
T3	p 391 507	in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .
T4	p 734 751	patients with MDS
T5	p 1337 1387	patients with AML or MDS who received chemotherapy
T6	i 33 79	itraconazole capsules and fluconazole capsules
T7	i 321 328	capsule
T8	i 335 351	of fluconazole (
T9	i 366 380	itraconazole (
T10	i 574 586	itraconazole
T11	i 649 660	fluconazole
T12	i 882 894	itraconazole
T13	i 913 924	fluconazole
T14	i 1152 1163	fluconazole
T15	i 1227 1239	itraconazole
T16	i 1413 1425	itraconazole
T17	i 1501 1514	fluconazole .
T18	o 550 566	fungal infection
T19	o 669 683	Adverse events
T20	o 853 863	infections
T21	o 1056 1062	counts
T22	o 1122 1144	frequency of infection
T23	o 1324 1333	tolerated